The Australian subsidiary of CSL Behring is set to develop a plasma-derived therapeutic for the treatment of serious complications in Covid-19 patients.

The company intends to focus on patients whose infection is progressing to the requirement for ventilation.

Named Covid-19 Immunoglobulin, the therapeutic will be developed by CSL Behring Australia at its manufacturing facility in Broadmeadows, Victoria.

Read the full article here